Drug Trial Radar · NCT02777008
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
May 2016
Primary completion
Dec 2016
Study completion Mar 2017
Sponsor
- Lead sponsor
- Concert PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 19, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Single- and multiple-ascending dose study of CTP-543 in healthy volunteers.
Conditions
- Healthy
Interventions
CTP-543Drug
Placebo for CTP-543Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 24 hours
- Measurement of CTP-543 exposure in plasma under fasted conditionsTime frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.